| In millions, except per share items | Mar-31-18 | Dec-31-17 | Sep-30-17 | Jun-30-17 | Mar-31-17 | Dec-31-16 | Sep-30-16 | Jun-30-16 |
| | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Revenues: |
| Epinephrine Auto-Injector family (generic Adrenaclick®) | 14.8 | 23.4 | 40.5 | 29.8 | 20.3 | 14.0 | 39.3 | 26.8 |
| Oxymorphone HCI ER family | | 16.0 | 16.4 | 17.3 | | 20.8 | 22.6 | 16.6 |
| Budesonide family | | 10.5 | | 15.2 | | | | |
| Fenofibrate family | | | | | | 13.5 | 14.5 | 18.2 |
| Diclofenac Sodium Gel family (generic Solaraze®) | | | 13.3 | | | 8.2 | | |
| Amphetamine Salts ER (CII) family (generic Adderall®) | | | | | 12.2 | | | |
| Other | 68.4 | 63.1 | 81.0 | 88.6 | 101.7 | 82.7 | 98.9 | 60.0 |
| Impax Generics revenues | 83.1 | 112.9 | 151.1 | 150.9 | 134.1 | 139.2 | 175.3 | 121.7 |
| Revenue growth [+] | -38.0% | -18.9% | -13.8% | 24.0% | -21.1% | -38.6% | -3.0% | -30.3% |
| Epinephrine Auto-Injector family (generic Adrenaclick®) | -27.2% | 67.1% | 3.0% | 10.9% | | | | |
| Oxymorphone HCI ER family | | -22.9% | -27.7% | 4.0% | | | | |
| Amphetamine Salts ER (CII) family (generic Adderall®) | | | | | -43.4% | | | |
| Gross profit | -11.9 | 112.9 | 10.0 | 150.9 | 30.8 | 139.2 | 60.3 | 121.7 |
| Gross margin | -14.3% | 100.0% | 6.6% | 100.0% | 23.0% | 100.0% | 34.4% | 100.0% |
| Selling, general and administrative | 7.6 | 8.2 | 5.6 | 8.0 | 6.5 | 8.1 | 6.1 | 1.6 |
| Research and development | 9.6 | 12.6 | 12.2 | 21.0 | 17.4 | 15.9 | 15.4 | 16.1 |
| EBIT | -113.7 | -215.6 | -21.5 | 12.6 | -38.8 | -212.1 | -233.3 | 18.5 |
| EBIT margin | -136.7% | -190.9% | -14.2% | 8.4% | -28.9% | -152.3% | -133.1% | 15.2% |
| Pre-tax income | -113.7 | 49.6 | -21.5 | | -38.8 | 174.3 | -233.3 | |
| Pre-tax margin | -136.7% | 44.0% | -14.2% | | -28.9% | 125.2% | -133.1% | |
| Net income | | | | | | | | |
| Net margin | | | | | | | | |
| |
| Revenue Mix | 58.4% | 61.7% | 73.2% | 74.7% | 72.7% | 70.2% | 76.9% | 70.5% |
| EBIT Mix | | | | | | | | 421.4% |